Literature DB >> 27056357

Ertapenem-Induced Hallucinations and Delirium in an Elderly Patient.

John J Veillette1, Puja Van Epps.   

Abstract

OBJECTIVE: To report a case of ertapenem-induced hallucinations and delirium in an elderly, morbidly obese patient. SETTING/PRACTICE DESCRIPTION: A 71-year-old male was receiving intravenous antibiotics at an outside nursing facility through our Outpatient Parenteral Antimicrobial Therapy (OPAT) program, which has enrolled more than 800 patients since 2009. He was admitted to our medical center, a 673-bed tertiary health care facility, which provides care to more than 100,000 veterans in Northeast Ohio. MAIN OUTCOME/
RESULTS: Our patient was admitted with an acute heart failure exacerbation after being discharged four weeks prior with a plan to complete six weeks of intravenous daptomycin 1 g daily and ertapenem 1 g daily for a left-calcaneal diabetic foot osteomyelitis. On initial exam, in addition to volume overload, he was noted to have fluctuating orientation, hallucinations, and suicidal ideations, which were all a significant change from his baseline mentation. A physical, laboratory, and radiologic workup revealed no conclusive etiology for his symptoms, at which point drug-induced toxicity was suspected. Upon discontinuation of ertapenem, the patient rapidly improved over the next 72 hours, including return to baseline mentation and absence of any suicidal thoughts. Use of the Naranjo probability scale indicated a probable relationship between ertapenem and the adverse effects experienced by our patient.
CONCLUSION: This case report and literature review demonstrates the potential severity of non-seizure-related neurotoxicity associated with ertapenem. As this toxicity can be life-threatening if unrecognized, it is crucial that clinicians across all practice settings be proactive in detecting and preventing it.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27056357     DOI: 10.4140/TCP.n.2016.207

Source DB:  PubMed          Journal:  Consult Pharm        ISSN: 0888-5109


  6 in total

1.  Ertapenem-associated neurotoxicity in the spinal cord injury (SCI) population: A case series.

Authors:  Ursula C Patel; Mallory A Fowler
Journal:  J Spinal Cord Med       Date:  2017-09-06       Impact factor: 1.985

2.  Pharmacokinetics of Ertapenem in Sheep (Ovis aries) with Experimentally Induced Urinary Tract Infection.

Authors:  Joe S Smith; David J Borts; Clare C Slagel; Suzanne M Rajewski; Alain Bousquet-Melou; Aude A Ferran; Paul J Plummer; Jon P Mochel
Journal:  Comp Med       Date:  2019-10-03       Impact factor: 0.982

Review 3.  The Pharmacology of Visual Hallucinations in Synucleinopathies.

Authors:  Mirella Russo; Claudia Carrarini; Fedele Dono; Marianna Gabriella Rispoli; Martina Di Pietro; Vincenzo Di Stefano; Laura Ferri; Laura Bonanni; Stefano Luca Sensi; Marco Onofrj
Journal:  Front Pharmacol       Date:  2019-12-09       Impact factor: 5.810

Review 4.  Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK.

Authors:  Ann L N Chapman; Sanjay Patel; Carolyne Horner; Helen Green; Achyut Guleri; Sara Hedderwick; Susan Snape; Julie Statham; Elizabeth Wilson; Mark Gilchrist; R Andrew Seaton
Journal:  JAC Antimicrob Resist       Date:  2019-08-26

5.  Ertapenem-induced encephalopathy.

Authors:  Rebecca Adams; Priya Chopra; Richard Miranda; Aaron Calderon
Journal:  BMJ Case Rep       Date:  2020-06-01

6.  Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).

Authors:  Chengwen Teng; Christopher R Frei
Journal:  Drugs Real World Outcomes       Date:  2021-07-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.